Lake Street raised the firm’s price target on Koru Medical (KRMD) to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission for the oncology indication prior to year-end is “a meaningful catalyst, expects 2026 to be another year of growth acceleration and improving leverage, supporting revenue upside and multiple expansion, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRMD:
